Pathway-Based Evaluation in Early Onset Colorectal Cancer Suggests Focal Adhesion and Immunosuppression along with Epithelial-Mesenchymal Transition

Colorectal cancer (CRC) has one of the highest incidences among all cancers. The majority of CRCs are sporadic cancers that occur in individuals without family histories of CRC or inherited mutations. Unfortunately, whole-genome expression studies of sporadic CRCs are limited. A recent study used microarray techniques to identify a predictor gene set indicative of susceptibility to early-onset CRC. However, the molecular mechanisms of the predictor gene set were not fully investigated in the previous study. To understand the functional roles of the predictor gene set, in the present study we applied a subpathway-based statistical model to the microarray data from the previous study and identified mechanisms that are reasonably associated with the predictor gene set. Interestingly, significant subpathways belonging to 2 KEGG pathways (focal adhesion; natural killer cell-mediated cytotoxicity) were found to be involved in the early-onset CRC patients. We also showed that the 2 pathways were functionally involved in the predictor gene set using a text-mining technique. Entry of a single member of the predictor gene set triggered a focal adhesion pathway, which confers anti-apoptosis in the early-onset CRC patients. Furthermore, intensive inspection of the predictor gene set in terms of the 2 pathways suggested that some entries of the predictor gene set were implicated in immunosuppression along with epithelial-mesenchymal transition (EMT) in the early-onset CRC patients. In addition, we compared our subpathway-based statistical model with a gene set-based statistical model, MIT Gene Set Enrichment Analysis (GSEA). Our method showed better performance than GSEA in the sense that our method was more consistent with a well-known cancer-related pathway set. Thus, the biological suggestion generated by our subpathway-based approach seems quite reasonable and warrants a further experimental study on early-onset CRC in terms of dedifferentiation or differentiation, which is underscored in EMT and immunosuppression.

[1]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[2]  T. Jenssen,et al.  A literature network of human genes for high-throughput analysis of gene expression , 2001, Nature Genetics.

[3]  K. Hatakeyama,et al.  Expression of Fas ligand is an early event in colorectal carcinogenesis , 2001, Journal of surgical oncology.

[4]  M. Kaneko,et al.  CD15 expression in mature granulocytes is determined by alpha 1,3-fucosyltransferase IX, but in promyelocytes and monocytes by alpha 1,3-fucosyltransferase IV. , 2001, The Journal of biological chemistry.

[5]  Hisashi Narimatsu,et al.  CD15 Expression in Mature Granulocytes Is Determined by α1,3-Fucosyltransferase IX, but in Promyelocytes and Monocytes by α1,3-Fucosyltransferase IV* , 2001, The Journal of Biological Chemistry.

[6]  J. Bach Regulatory T cells under scrutiny , 2003, Nature Reviews Immunology.

[7]  J. Bach Regulatory lymphocytes: Regulatory T cells under scrutiny , 2003, Nature Reviews Immunology.

[8]  A. Mercurio,et al.  Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. , 2003, Molecular biology of the cell.

[9]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[10]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[11]  S. Fu,et al.  TGF‐β Induces Foxp3 + T‐Regulatory Cells from CD4 + CD25 − Precursors , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  William R Sellers,et al.  The biology and clinical relevance of the PTEN tumor suppressor pathway. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  N. Zhang,et al.  TGF-beta induces Foxp3 + T-regulatory cells from CD4 + CD25 - precursors. , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  Seong-Jin Kim,et al.  Transforming growth factor-beta : biology and clinical relevance. , 2005, Journal of biochemistry and molecular biology.

[15]  Seong-Jin Kim,et al.  Transforming Growth Factor-β: Biology and Clinical Relevance , 2005 .

[16]  Gábor Csárdi,et al.  The igraph software package for complex network research , 2006 .

[17]  A. Chorny,et al.  Vasoactive intestinal peptide induces CD4+,CD25+ T regulatory cells with therapeutic effect in collagen-induced arthritis. , 2006, Arthritis and rheumatism.

[18]  H. Andreyev,et al.  A “field change” of inhibited apoptosis occurs in colorectal mucosa adjacent to colorectal adenocarcinoma , 2006, Journal of Clinical Pathology.

[19]  Robert D. Schreiber,et al.  Interferons, immunity and cancer immunoediting , 2006, Nature Reviews Immunology.

[20]  Hailing Lu,et al.  Immunoediting of Cancers May Lead to Epithelial to Mesenchymal Transition1 , 2006, The Journal of Immunology.

[21]  T. Wu,et al.  Prospects of RNA interference therapy for cancer , 2006, Gene Therapy.

[22]  E. González-Rey,et al.  A Novel Mechanism for Immunosuppression: from Neuropeptides to Regulatory T Cells , 2006, Journal of Neuroimmune Pharmacology.

[23]  Richard A Flavell,et al.  Transforming growth factor-beta regulation of immune responses. , 2006, Annual review of immunology.

[24]  K. Ho,et al.  A Susceptibility Gene Set for Early Onset Colorectal Cancer That Integrates Diverse Signaling Pathways: Implication for Tumorigenesis , 2007, Clinical Cancer Research.

[25]  M. Manjili,et al.  Tumor immunoediting and immunosculpting pathways to cancer progression. , 2007, Seminars in cancer biology.

[26]  Craig Murdoch,et al.  The role of myeloid cells in the promotion of tumour angiogenesis , 2008, Nature Reviews Cancer.

[27]  R. Mirimanoff,et al.  CYR61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. , 2008, Cancer research.

[28]  M. Schwaiger,et al.  TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. , 2008, Cancer cell.

[29]  J. Parsons,et al.  Focal Adhesion Kinase: Targeting Adhesion Signaling Pathways for Therapeutic Intervention , 2008, Clinical Cancer Research.

[30]  B. Jiang,et al.  PI3K/PTEN signaling in tumorigenesis and angiogenesis. , 2008, Biochimica et biophysica acta.

[31]  J. Niederkorn Immune escape mechanisms of intraocular tumors , 2009, Progress in Retinal and Eye Research.

[32]  Pooja Mittal,et al.  A novel signaling pathway impact analysis , 2009, Bioinform..

[33]  R. Weinberg,et al.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits , 2009, Nature Reviews Cancer.

[34]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[35]  M. Mihm,et al.  Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. , 2009, Cancer immunity.

[36]  Z. Szallasi,et al.  Evaluation of Microarray Preprocessing Algorithms Based on Concordance with RT-PCR in Clinical Samples , 2009, PloS one.

[37]  M. Bertagnolli,et al.  Molecular origins of cancer: Molecular basis of colorectal cancer. , 2009, The New England journal of medicine.

[38]  M. Röcken Early tumor dissemination, but late metastasis: insights into tumor dormancy. , 2010, The Journal of clinical investigation.

[39]  A. Prasse,et al.  Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. , 2010, American journal of respiratory and critical care medicine.

[40]  D. Mcgregor,et al.  Cyr61/CCN1 signaling is critical for epithelial-mesenchymal transition and stemness and promotes pancreatic carcinogenesis , 2011, Molecular Cancer.

[41]  K. Reavis,et al.  CCN1 induces a reversible epithelial–mesenchymal transition in gastric epithelial cells , 2010, Laboratory Investigation.

[42]  A. Yuryev,et al.  Atlas of Signaling for Interpretation of Microarray Experiments , 2010, PloS one.

[43]  D. Radisky,et al.  Immune promotion of epithelial-mesenchymal transition and generation of breast cancer stem cells. , 2010, Cancer research.

[44]  A. Bajo,et al.  Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1. , 2010, Cancer letters.

[45]  Susumu Goto,et al.  KEGG for representation and analysis of molecular networks involving diseases and drugs , 2009, Nucleic Acids Res..

[46]  S. Lim,et al.  p190RhoGEF (Rgnef) promotes colon carcinoma tumor progression via interaction with focal adhesion kinase. , 2011, Cancer research.

[47]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[48]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[49]  Yuzhuo Wang,et al.  The immunoregulatory mechanisms of carcinoma for its survival and development , 2011, Journal of experimental & clinical cancer research : CR.